New Developments in MS Treatment and Lifestyle Factors.
Orelabrutinib, a Bruton’s tyrosine kinase inhibitor, has shown promising results in reducing brain lesions in a Phase 2 trial for relapsing-remitting multiple sclerosis. A Phase 2 clinical trial for foralumab, an antibody-based nasal spray, is set to launch later this year for people with nonactive secondary progressive MS. Research suggests that adhering to high-quality diets such as McDougall, paleo, Swank, and Overcoming MS may help ease depression in MS patients. A small study in Iran suggests that drinking coffee and tea may protect against MS, but the self-reporting survey used in the study has limitations.
